The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessAbstract
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During the time between initiation and completion of the FIDELIO-DKD and FIGARO-DKD trials, numerous rigorous clinical trials demonstrated large kidney and cardiovascular bene fi ts of SGLT2i (Section 1.3 above), and SGLT2i became an established fi rst-line treatment for T2D with CKD.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [143]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prioritization of SGLT2i therapy in high-risk patients such as those with CKD is consistent with the recommendations from other professional societies including the American College of Cardiology (ACC), 142 the joint statement by the ADA and the European Association of the Study of Diabetes (EASD), 143 and the joint guideline by the European Society of Cardiology (ESC) and EASD.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
ResultDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citationRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,000
Polypharmacy in diabetes: A nation-wide, pharmacy-based, observational study
Larger, É., Alexandre‐Heymann, L., Pilet, S., Raoul, T., Perray, L., & Maravic, M. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100088 · Cited by 5
Thomsen, R. W., Christensen, L. B., Kahlert, J. A., Knudsen, J. S., Ustyugova, A., Sandgaard, S., Holmgaard, P., Ehlers, L. H., & Sørensen, H. T. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01323-y · Cited by 5
Antsiferov, M. B., Demidov, N. A. D., Balberova, M. A., Lobanova, O. V., Mudrikova, I. G., & Gusenbekova, D. G. (2022) · Diabetes Mellitus · doi:10.14341/dm12929 · Cited by 5
Guo, L., Li, L., Yu, Q., Wang, N., Chen, J., Xi, Y., Wang, H., Wang, Y., & Xu, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15252 · Cited by 5
Cao, X., & Pei, X. (2023) · Technology and Health Care · doi:10.3233/thc-230811 · Cited by 5
Leitgeb, E. P., Kerčmar, J., Bombek, L. K., Pohorec, V., Klemen, M. S., Rupnik, M. S., Gosak, M., Dolenšek, J., & Stožer, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1315520 · Cited by 6
Aldahmani, K. M., Suliman, M., Hafidh, K., & Beshyah, S. (2024) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0044-1786013 · Cited by 5
John, M., Gopinath, D., & Oommen, T. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000509045 · Cited by 5
Wilke, T., Mueller, S., Fuchs, A., Kaltoft, M. S., Kipper, S., & Cel, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00903-0 · Cited by 5
Avogaro, A., Barillà, F., Cavalot, F. L., Consoli, A., Federici, M., Mancone, M., Paolillo, S., Pedrinelli, R., Perseghin, G., Filardi, P. P., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.029 · Cited by 5
Sex-disparities in risk factors and atherosclerosis cardiovascular disease in diabetic patients
Sun, Y., Dong, Y., Cui, L., Li, G., Sun, Y., & Hao, Z. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1917930 · Cited by 5
Rossing, P. R. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab243 · Cited by 7
Self-citationPatoulias, D., Papadopoulos, C. E., Kassimis, G., Karagiannis, A. I., & Doumas, M. N. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.08.009 · Cited by 5
Machine Learning Refutes Loss of Smell as a Risk Indicator of Diabetes Mellitus
Lötsch, J., Haehner, A., Schwarz, P. E. H., Tselmin, S., & Hummel, T. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214971 · Cited by 5
Peralta, F. G., Mareque, M., Muñoz, Á., Maderuelo, M., & Casado, M. Á. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01178-9 · Cited by 6
Kamoshima, H., Nomoto, H., Yamashita, K., Takahashi, Y., Tsuchida, K., Kuwabara, S., Miya, A., Cho, K. Y., Kameda, H., Nakamura, A., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0573 · Cited by 5
L-ergothioneine; a potential adjuvant in the management of diabetic nephropathy
Dare, A., Channa, M. L., & Nadar, A. (2021) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2021.100033 · Cited by 5
Cardelo, M. P., Alcala-Diaz, J. F., Gutierrez-Mariscal, F. M., López-Moreno, J., Villasanta‐Gonzalez, A., Larriva, A. P. A.-D., de la Cruz, S., Delgado‐Lista, J., Rodríguez-Cantalejo, F., Luque, R. M., et al. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100652 · Cited by 6
Coke, L. A., DEEDWANIA, P. C., Hinnen, D., Magwire, M., & Miller, N. H. (2022) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000661 · Cited by 5
The GenoDiabMar Registry: A Collaborative Research Platform of Type 2 Diabetes Patients
Sierra, A., Otero, S., Rodríguez, E., Faura, A., Vera, M., Riera, M., Palau, V., Durán, X., Costa-Garrido, A., Sans, L., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051431 · Cited by 5
ADA Standards of Medical Care in Diabetes 2022 - what's new?
Škrha, J. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.017 · Cited by 6
Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
Karásek, D. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.018 · Cited by 5
The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice
Martens, P., Mathieu, C., & Vanassche, T. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2076307 · Cited by 5
Self-citationEvans, M., Berry, S., Nazeri, A., Malkin, S. J. P., Ashley, D., Hunt, B., & Bain, S. C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14917 · Cited by 5
Tamaki, J., Ogawa, S., Fujimori, K., Ishii, S., Nakatoh, S., Okimoto, N., Kamiya, K., & Iki, M. (2022) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-022-01372-0 · Cited by 5
A Review of National Level Guidelines for Risk Management of Cardiovascular and Diabetic Disease
Pandit, R., Pandit, T., Goyal, L., & Ajmera, K. M. (2022) · Cureus · doi:10.7759/cureus.26458 · Cited by 7
Kim, J., Bae, Y., Lee, J., Kim, Y.-S., Kim, Y., You, H., Kim, H.-S., Choi, E.-A., Han, Y.-E., & Kang, H. (2021) · Medicine · doi:10.1097/md.0000000000025045 · Cited by 5
Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
Du, L., Qin, J., Wang, D., Zhao, Y., Xu, N., & Wu, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.987025 · Cited by 5
Kılıç, Y., Dalkılıç, S., Dalkılıç, L. K., Özdemir, E., UĞURLU, F. M., Pala, R., Yıldız, Y. A., Hepsert, S., & Ayılgan, E. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01893-4 · Cited by 4
Kempeneers, M. A., Issa, Y., Ali, U. A., Bruno, M. J., van Geenen, E. J. M., van Hooft, J. E., Römkens, T. E. H., Siersema, P. D., Spanier, B. W. M., Yahya, I., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001937 · Cited by 4
Al‐Ozairi, E., Narula, K., Miras, A. D., Taghadom, E., Samad, A. E., Kandari, J. A., Alyosef, A., Mashankar, A., Al‐Najim, W., & le Roux, C. W. (2024) · Trials · doi:10.1186/s13063-024-07930-3 · Cited by 4
Chiu, C., Chiu, Y.-P., Yip, H., Ji, H.-R., Cho, D., Cheng, I. H.-J., & Chen, C.-Y. (2024) · Neuroepidemiology · doi:10.1159/000539001 · Cited by 4
Rural-Urban Disparities in the Uptake of New Diabetes Medications
Zhu, B., Dong, D., Luo, J., & Glied, S. (2024) · Diabetes Spectrum · doi:10.2337/ds23-0075 · Cited by 5
Deng, X.-L., Wu, R., Lin, X.-X., Liang, J., & Huang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1514783 · Cited by 5
Liu, B., Huang, R., Zhang, W., Tian, J. H., Xian, Y., & Chen, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-02394-0 · Cited by 5
Benouchenne, D., Djeghim, H., Benslama, O., Alsaeedi, H., Cornu, D., Bechelany, M., & Barhoum, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1592468 · Cited by 4
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin
Guo, L., Sun, Z., Zhang, L., Qin, G., Li, Y., Chen, X., Xu, N., Su, X., Li, M. T., Sun, J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.15622 · Cited by 4
SGLT2-gátlók – diabetológián túlmutató előnyökkel rendelkező antihyperglykaemiás szerek
Jermendy, G. (2021) · Cardiologia Hungarica · doi:10.26430/chungarica.2021.51.1.39 · Cited by 4
Blonde, L., Fainberg, U., Kaltoft, M. S., Mosenzon, O., Ramesh, C. K., & Rea, R. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14464 · Cited by 4
Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967319 · Cited by 5
Srivastav, V. K., & Tiwari, M. (2021) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.857 · Cited by 4
Wretlind, A., Zobel, E. H., de Zawadzki, A., Ripa, R. S., Curovic, V. R., von Scholten, B. J., Mattila, I. M., Hansen, T. W., Kjær, A., Vestergaard, H., et al. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.856485 · Cited by 4
Self-citationWang, X., Wu, G., Shen, D., Zhang, X., & Yang, W. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02128-y · Cited by 4
Sanctis, V. D., Soliman, A. T., Tzoulis, P., Daar, S., Kattamis, A., Delaporta, P., Karimi, M., Yassin, M. A., Zarei, T., Saki, F., et al. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i2.12056 · Cited by 4
Longato, E., Camillo, B. D., Sparacino, G., Avogaro, A., & Fadini, G. P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01600-x · Cited by 4
Li, L., Wang, S., Huang, G., & You, J. (2022) · Medicine · doi:10.1097/md.0000000000030693 · Cited by 4
Zhang, X., Yip, T. C., Tse, Y., Hui, V. W., Li, G., Lin, H., Liang, L. Y., Lai, J. C., Lai, M. S., Cheung, J. T. K., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17428 · Cited by 4
Raimondo, M., Prestinaci, F., Aureli, F., D’Ettorre, G., & Gaudiano, M. C. (2023) · Frontiers in Analytical Science · doi:10.3389/frans.2023.1091764 · Cited by 4
Bongaerts, B. W. C., Kuß, O., Bonnet, F., Chen, H., Cooper, A., Fenici, P., Gomes, M. B., Hammar, N., Ji, L., Khunti, K. K., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15050 · Cited by 4
Ouchi, D., Giner‐Soriano, M., Vilaplana-Carnerero, C., Monfà, R., Torres, F., & Morros, R. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110777 · Cited by 4
Lin, F., He, R. X., Ling, B., Wang, L., Jiang, T., & Yu, B. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.011 · Cited by 4
Han, L., Chen, X., Wan, D.-W., Xie, M., & Ouyang, S. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02516-4 · Cited by 4
Gobezie, M. Y., Tesfaye, N. A., Solomon, T., Demessie, M. B., Wendie, T. F., Belayneh, Y. M., Baye, A. M., & Hassen, M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1399944 · Cited by 5
Hösli, P., Renström, F., Laimer, M. W., Cavelti‐Weder, C., Gastaldi, G., Lehmann, R., & Brändle, M. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004108 · Cited by 4
Krishnan, A., Schneider, C. V., Arkenau, H., Mauro, E., Forner, A., Butsch, W. S., Walsh, D., & Alqahtani, S. A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100370 · Cited by 6
Sharrack, N., Knott, K. D., Gulsin, G. S., Kotecha, T., Brown, L., Yeo, J. L., Porcari, A., Adam, R. D., Thirunavukarasu, S., Chowdhary, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-77280-2 · Cited by 5
Yao, Y., Liu, J., Miao, Q., Zhu, X., Sun, L., Hua, W., Zhang, N., Huang, G., Ruan, R. R., Cheng, Y., et al. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106624 · Cited by 4
Tsuda, A., Mori, K., Uedono, H., Nakatani, S., Nagata, Y., Kurajoh, M., Yamada, S., Morioka, T., Ishimura, E., Uchida, J., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-02020-y · Cited by 4
Odawara, M., Matsuhisa, M., Hirose, T., Koshida, R., Senda, M., Tanaka, Y., & Terauchi, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1785430 · Cited by 4
Zheng, H., Toupin‐April, K., An, Y., He, S., Sigal, R. J., Coyle, D., Wells, G. A., & Li, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108471 · Cited by 4
Yalım, Z., Aldemir, M., & Emren, S. V. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.08.002 · Cited by 4
Sulfonylurea derivatives and risk of hypoglycaemia in type 2 diabetic patients
Svěcený, J., Jirušková, J., Hrach, K., Radovnická, L., & Laštůvka, J. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.114 · Cited by 6
Ghouri, N., Javed, H., & Sattar, N. A. (2020) · Current Diabetes Reviews · doi:10.2174/1573399817666201228120725 · Cited by 4
Hu, L., Ma, J., Gu, L., Chen, P., Chen, L., & Zhang, X. (2021) · BioMed Research International · doi:10.1155/2021/6698085 · Cited by 4
Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
Mkrtumyan, A. M., Маркова, Т. Н., & Mishchenko, N. K. (2021) · Diabetes Mellitus · doi:10.14341/dm12541 · Cited by 4
Dardano, A., Aragona, M., Daniele, G., Miccoli, R., & Prato, S. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.847778 · Cited by 4
Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism
Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Ainola, M., Hakkarainen, A., Lundbom, N., Sihlbom, C., Thorsell, A., Andersson, L., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1187 · Cited by 4
Bae, J. P., KADZIOLA, Z. A., Liu, D., Chinthammit, C., Boye, K. S., & Mather, K. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01289-x · Cited by 4
Sim, R., Chong, C. W., Loganadan, N. K., Saidoung, P., Adam, N. L., Hussein, Z. B., Chaiyakunapruk, N., & Lee, S. W. H. (2023) · Value in Health Regional Issues · doi:10.1016/j.vhri.2023.05.006 · Cited by 4
Ortiz-Zúñiga, Á., Simó‐Servat, O., Amigó, J., Sánchez, M., Morer, C., Franch‐Nadal, J., Mayor, R., Snel, T., Simó, R., & Hernández, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196364 · Cited by 4
Erukulapati, R. S., Manikandan, R. M., Jakkidi, L. R., Sathyanarayana, S. O., Ayyagari, U., Aswathiah, S., Nalla, S., Sampath, S. K., Manohar, S. P., Shah, S. C., et al. (2024) · Clinical Diabetology · doi:10.5603/cd.98136 · Cited by 5
Patoulias, D., Boulmpou, A., Imprialos, K. P., Stavropoulos, K., Papadopoulos, C. E., & Doumas, M. N. (2021) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2021.04.002 · Cited by 4
Prediabetes. A new paradigm for early prevention of cardiovascular disease
Demidova, T. Y., & Plakhotnyaya, V. M. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-14-124-132 · Cited by 4
Román, G. (2021) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2021.331 · Cited by 4
Das, B., Sheikh, A., Ahmed, B., & Islam, N. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.5.3901 · Cited by 6
Brunetti, A., & Aversa, A. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102185 · Cited by 4
Rizzo, M., Cosentino, F., & Mantzoros, C. S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2108400 · Cited by 4
Araldi, E., Jutzeler, C. R., & Ristow, M. (2023) · medRxiv · doi:10.1101/2023.05.19.23290214 · Cited by 4
Inceu, G. V., Crăciun, A.-E., Ciobanu, D. M., Berchisan, A., Fodor, A., Bala, C., Roman, G., & Rusu, A. (2025) · Medicina · doi:10.3390/medicina61081343 · Cited by 3
Wang, Q., Jiang, F., Xu, Y., Lei, Y., Zhang, L., & Sun, X. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01569-2 · Cited by 4
The Role of Gender and Physician Specialty in Patient Experience Scores
Gulko, H. E., Katzap, E., Izard, S. M., Mieres, J. H., Horowitz, D. L., & Kim, A. C. (2025) · Journal of Women s Health · doi:10.1177/15409996251395421 · Cited by 3
Current and emerging approaches to managing peripheral artery disease: a specialist review
Mohammadi, A., Hussein, L., Yahyavi, A., & Shishehbor, M. H. (2026) · Heart · doi:10.1136/heartjnl-2025-326532 · Cited by 3
Pujante, P., Felgueroso, C. A., Ares, J., Morales-Sánchez, P., Lambert, C., Escobedo, R. R., Rodríguez‐Rodero, S., Delgado, E., & Torre, E. L. M. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.10.008 · Cited by 2
Basile, G. (2022) · The Journal of AMD · doi:10.36171/jamd22.25.2.5 · Cited by 3
First-in-Class Oral Semaglutide
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
Wang, H.-J., Zhang, L.-B., Sun, S.-P., Yan, Q., Gao, Z., Fu, F., & Qu, M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i2.287 · Cited by 3
Villar‐Taibo, R., Sanz-Pastor, A. G., Fernández-Rubio, E., Galindo, D. E. B., Simó-Servat, A., & Ampudia‐Blasco, F. J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0524 · Cited by 3
McCormick, T. A., Kramer, J. B., Liles, E. G., Amos, Q., Martin, J. P., & Adams, J. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003792 · Cited by 3
Vlacho, B., Molló, À., Gratacòs, M., Mata‐Cases, M., Rubinat, E., Berenguera, A., Cos, X., Franch‐Nadal, J., & Mauricio, D. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.05.001 · Cited by 3
Chong, G. Y., Kaur, S., Ruzita, A., Mok, K. H. W., Tan, H., Loy, S., Chen, L.-W., Siah, W. Y., Lim, G., Chee, Y.-Y., et al. (2024) · Chronobiology International · doi:10.1080/07420528.2024.2360742 · Cited by 4
The Effect of Metformin on some Physiological Traits in Rats with Alloxan-Induced Diabetes
Rashid, A. H., Muhammad, M. J., & Hussein, F. F. (2024) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/1371/6/062008 · Cited by 3
Abdelgadir, E., Bashier, A. M., Ashfaq, F., Hassanein, M. M., & Beshyah, S. (2024) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0044-1791484 · Cited by 3
Agarwal, R., Nangaku, M., Chen, L., Wang, A. Y.-M., Yanagita, M., Bavanandan, S., Satirapoj, B., Prasad, N., Lim, S. K., Sriwijitkamol, A., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000909 · Cited by 4
Aberle, J., Lautenbach, A., Meyhöfer, S., Schmid, S. M., Selig, L., & Blüher, M. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1179-2778 · Cited by 3
Gill, G. S., Latif, A., Hilleman, D. E., Lavie, C. J., & Alla, V. M. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100878 · Cited by 3
Chowdhury, T. A., & Ali, O. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0144 · Cited by 3
¿La insulina es un todoterreno?
Cuenca, A. M. C. (2021) · doi:10.52102/insulina/art-4 · Cited by 3
Cómo podemos optimizar la insulinización
Cosiales, P. B. (2021) · doi:10.52102/insulina/art-3 · Cited by 3
Sukhareva, O. Y., Zuraeva, Z. T., & Shamhalova, M. (2022) · Diabetes Mellitus · doi:10.14341/dm12864 · Cited by 4
Pariente, A. E., Rosa, I., Dharancy, S., Hanslik, B., & for the Investigators of PERSEPT Study (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002369 · Cited by 3
Metadata
- Authors
- Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of Copenhagen (DK)
- Università Cattolica del Sacro Cuore (IT)
- Universitair Ziekenhuis Leuven (BE)
- Duke University (US)
- University of Leicester (GB)
- Corresponding author
- Davies, Melanie J.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-19
- Volume
- 43
- Issue
- 2
- Pages
- 487-493
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6971782
- OpenAlex
- W4253996779
- Cited by
- 1,192
- References
- 21
- Citations by year
- 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
- FWCI
- 155.76
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-07-01)
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- Lirias (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Funders
- American Diabetes Association
- European Association for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
